Downregulation of Metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 6, 2012, Pages 918-926

  Yan, Dong Wang ^a   Fan, Jun Wei ^a   Yu, Zhen hai ^b   Li, Ming xue ^b   Wen, Yu Gang ^a   Li, Da Wei ^a   Zhou, Chong Zhi ^a   Wang, Xiao Liang ^a   Wang, Quan ^a   Tang, Hua Mei ^a   Peng, Zhi Hai ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Colon carcinogenesis; Epigenetics; Loss of heterozygosity; Metallothionein; Microarray

Indexed keywords

METALLOTHIONEIN; METALLOTHIONEIN 1F; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL INVASION; CELL LINE; CELL MIGRATION; CELL SURVIVAL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; METALLOTHIONEIN; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84858983390     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.02.021     Document Type: Article

References (53)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA. Cancer J. Clin. 2009, 59:225-249.
2. Zhang S., Cui Y., Weng Z., Gong X., Chen M., Zhong B. Changes on the disease pattern of primary colorectal cancers in Southern China: a retrospective study of 20years. Int. J. Colorectal Dis. 2009, 24:943-949.
3. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099.
4. Pino M.S., Chung D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010, 138:2059-2072.
5. Luo L., Shen G.Q., Stiffler K.A., Wang Q.K., Pretlow T.G., Pretlow T.P. Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer. Carcinogenesis 2006, 27:1153-1159.
6. Peng Z., Zhang F., Zhou C., Ling Y., Bai S., Liu W., et al. Genome-wide search for loss of heterozygosity in Chinese patients with sporadic colorectal cancer. Int. J. Gastrointest. Cancer 2003, 34:39-48.
7. Xiao X.Y., Zhou X.Y., Yan G., Sun M.H., Du X. Chromosomal alteration in Chinese sporadic colorectal carcinomas detected by comparative genomic hybridization. Diagn. Mol. Pathol. 2007, 16:96-103.
8. Eckschlager T., Adam V., Hrabeta J., Figova K., Kizek R. Metallothioneins and cancer. Curr. Protein Pept. Sci. 2009, 10:360-375.
9. Cherian M.G., Jayasurya A., Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 2003, 533:201-209.
10. Miles A.T., Hawksworth G.M., Beattie J.H., Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit. Rev. Biochem. Mol. Biol. 2000, 35:35-70.
11. Haq F., Mahoney M., Koropatnick J. Signaling events for metallothionein induction. Mutat. Res. 2003, 533:211-226.
12. Janssen A.M., van Duijn W., Kubben F.J., Griffioen G., Lamers C.B., van Krieken J.H., et al. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin. Cancer Res. 2002, 8:1889-1896.
13. Janssen A.M., van Duijn W., Oostendorp-Van De Ruit M.M., Kruidenier L., Bosman C.B., Griffioen G., et al. Metallothionein in human gastrointestinal cancer. J. Pathol. 2000, 192:293-300.
14. Ioachim E.E., Goussia A.C., Agnantis N.J., Machera M., Tsianos E.V., Kappas A.M. Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J. Clin. Pathol. 1999, 52:876-879.
15. Hishikawa Y., Kohno H., Ueda S., Kimoto T., Dhar D.K., Kubota H., et al. Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 2001, 61:162-167.
16. Dziegiel P., Forgacz J., Suder E., Surowiak P., Kornafel J., Zabel M. Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol. Histopathol. 2003, 18:401-407.
17. Sutoh I., Kohno H., Nakashima Y., Hishikawa Y., Tabara H., Tachibana M., et al. Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers. Dis. Colon Rectum 2000, 43:221-232.
18. Lee S., Bang S., Song K., Lee I. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol. Rep. 2006, 16:747-754.
19. Wilson A.J., Chueh A.C., Tögel L., Corner G.A., Ahmed N., Goel S., et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res. 2010, 70:609-620.
20. Fan J., Peng Z., Zhou C., Qiu G., Tang H., Sun Y., et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer 2008, 113:266-275.
21. O'Connell J.B., Maggard M.A., Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 2004, 96:1420-1425.
22. Yan D.W., Li D.W., Yang Y.X., Xia J., Wang X.L., Zhou C.Z., et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br. J. Cancer 2010, 103:961-969.
23. Mididoddi S., McGuirt J.P., Sens M.A., Todd J.H., Sens D.A. Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol. Lett. 1996, 85:17-27.
24. Tai S.K., Tan O.J., Chow V.T., Jin R., Jones J.L., et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am. J. Pathol. 2003, 163:2009-2019.
25. Payne S.R., Kemp C.J. Tumor suppressor genetics. Carcinogenesis 2003, 26:2031-2045.
26. Lu D.D., Chen Y.C., Zhang X.R., Cao X.R., Jiang H.Y., Yao L. The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale J. Biol. Med. 2003, 76:55-62.
27. Yi Y., Mirosevich J., Shyr Y., Matusik R., George A.L. Coupled analysis of gene expression and chromosomal location. Genomics 2005, 85:401-412.
28. Hawthorn L., Luce J., Stein L., Rothschild J. Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast. BMC Cancer 2010, 10:460.
29. Okuno K., Yasutomi M., Nishimura N., Arakawa T., Shiomi M., Hida J., et al. Gene expression analysis in colorectal cancer using practical DNA array filter. Dis. Colon Rectum 2001, 44:295-299.
30. Dziegiel P., Dumańska M., Forgacz J., Wojna A., Zabel M. Intensity of apoptosis as related to the expression of metallothionein (MT), caspase-3 (cas-3) and Ki-67 antigen and the survival time of patients with primary colorectal adenocarcinomas. Rocz. Akad. Med. Bialymst 2004, 49:5-7.
31. Schmitz K.J., Müller C.I., Reis H., Alakus H., Winde G., Baba H.A., et al. Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. Int. J. Colorectal Dis. 2009, 24:1287-1296.
32. Bruewer M., Schmid K.W., Krieglstein C.F., Senninger N., Schuermann G. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J. Surg. 2002, 26:726-731.
33. Laukens D., Peeters H., Waeytens A., Bogaert S., Cruyssen B.V., Elewaut D., et al. Reduced metallothionein expression in colonic Crohn's disease: evidence for it new disease-modifying gene. Gastroenterology 2008, 134:A457-A457.
34. Tran C.D., Sundar S., Howarth G.S. Dietary zinc supplementation and methotrexate-induced small intestinal mucositis in metallothionein-knockout and wild-type mice. Cancer Biol. Ther. 2009, 8:1662-1667.
35. Zhang B., Satoh M., Nishimura N., Suzuki J.S., Sone H., Aoki Y., et al. Metallothionein deficiency promotes mouse skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene. Cancer Res. 1998, 58:4044-4046.
36. Waalkes M.P., Liu J., Goyer R.A., Diwan B.A. Metallothionein-I/II double knockout mice are hypersensitive to lead-induced kidney carcinogenesis: role of inclusion body formation. Cancer Res. 2004, 64:7766-7772.
37. Suzuki J.S., Nishimura N., Zhang B., Nakatsuru Y., Kobayashi S., Satoh M., et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis 2003, 24:1123-1132.
38. Shibuya K., Nishimura N., Suzuki J.S., Tohyama C., Naganuma A., Satoh M. Role of metallothionein as a protective factor against radiation carcinogenesis. J. Toxicol. Sci. 2008, 33:651-655.
39. Takaishi M., Shimada A., Suzuki J.S., Satoh M., Nagase H. Involvement of metallothionein (MT) as a biological protective factor against carcinogenesis induced by benzo[a]pyrene (B[a]P). J. Toxicol. Sci. 2010, 35:225-230.
40. Sakurai A., Hara S., Okano N., Kondo Y., Inoue J., Imura N. Regulatory role of metallothionein in NF-kappaB activation. FEBS Lett. 1999, 455:55-58.
41. Ostrakhovitch E.A., Olsson P.E., Jiang S., Cherian M.G. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 2006, 580:1235-1238.
42. Hecht D., Jung D., Prabhu V.V., Munson P.J., Hoffman M.P., Kleinman H.K. Metallothionein promotes laminin-1-induced acinar differentiation in vitro and reduces tumor growth in vivo. Cancer Res. 2002, 62:5370-5374.
43. Stenram U., Ohlsson B., Tranberg K.G. Immunohistochemical expression of metallothionein in resected hepatic primary tumors and colorectal carcinoma metastases. APMIS 1999, 107:420-424.
44. Faller W.J., Rafferty M., Hegarty S., Gremel G., Ryan D., Fraga M.F., et al. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 2010, 20:392-400.
45. Tse K.Y., Liu V.W., Chan D.W., Chiu P.M., Tam K.F., Chan K.K., et al. Epigenetic alteration of the metallothionein 1E gene in human endometrial carcinomas. Tumour Biol. 2009, 30:93-99.
46. Sakamoto L.H., D.E. Camargo B., Cajaiba M., Soares F.A., Vettore A.L. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. Pediatr. Res. 2010, 67:387-393.
47. Park S.Y., Kwon H.J., Lee H.E., Ryu H.S., Kim S.W., Kim J.H., et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 2011, 458:73-84.
48. Lin Q., Geng J., Ma K., Yu J., Sun J., Shen Z., et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J. Cancer Res. Clin. Oncol. 2009, 135:1675-1684.
49. Giacomini C.P., Leung S.Y., Chen X., Yuen S.T., Kim Y.H., Bair E., et al. A gene expression signature of genetic instability in colon cancer. Cancer Res. 2005, 65:9200-9205.
50. Deng G., Chen A., Hong J., Chae H.S., Kim Y.S. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59:2029-2033.
51. John S., Briatka T., Rudolf E. Diverse sensitivity of cells representing various stages of colon carcinogenesis to increased extracellular zinc: implications for zinc chemoprevention. Oncol Rep. 2011, 25:769-780.
52. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 1971, 68:820-823.
53. Velasco A., Pallares J., Santacana M., Yeramian A., Dolcet X., Eritja N., et al. Loss of heterozygosity in endometrial carcinoma. Int. J. Gynecol. Pathol. 2008, 27:305-317.